BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31437546)

  • 21. Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: A case report.
    Numata S; Iwata Y; Okumura R; Arima M; Kobayashi T; Watanabe S; Suzuki K; Horiguchi M; Sugiura K
    J Dermatol; 2018 Jan; 45(1):113-114. PubMed ID: 28225147
    [No Abstract]   [Full Text] [Related]  

  • 22. Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma.
    Ediriwickrema LS; Liu CY; Kikkawa DO; Korn BS
    Ophthalmic Plast Reconstr Surg; 2019; 35(5):e121-e122. PubMed ID: 31373986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic inflammatory demyelinating polyradiculoneuropathy secondary to immune checkpoint inhibitors in melanoma patients.
    Patel AS; Snook RJ; Sehdev A
    Discov Med; 2019 Aug; 28(152):107-111. PubMed ID: 31926582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition.
    van den Brom RR; Abdulahad WH; Rutgers A; Kroesen BJ; Roozendaal C; de Groot DJ; Schröder CP; Hospers GA; Brouwer E
    Rheumatology (Oxford); 2016 Jun; 55(6):1143-5. PubMed ID: 27069016
    [No Abstract]   [Full Text] [Related]  

  • 25. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
    Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
    [No Abstract]   [Full Text] [Related]  

  • 26. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
    Alnabulsi R; Hussain A; DeAngelis D
    Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
    Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis.
    Abdelhafeez AAM; Shohdy KS; Ibrahim W
    Cancer Invest; 2020 Mar; 38(3):150-157. PubMed ID: 31977260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary.
    Uehara J; Yoshino K; Sugiyama E; Ohkuma K; Oaku S; Yamashita C; Hiura A; Fujisawa Y
    J Dermatol; 2020 Jun; 47(6):e237-e239. PubMed ID: 32270507
    [No Abstract]   [Full Text] [Related]  

  • 30. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
    Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
    J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
    JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
    Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
    Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
    Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Takotsubo-Like Syndrome in Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Ederhy S; Cautela J; Ancedy Y; Escudier M; Thuny F; Cohen A
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1187-1190. PubMed ID: 29550317
    [No Abstract]   [Full Text] [Related]  

  • 35. Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients.
    Heppt MV; Schlaak M; Eigentler TK; Kähler KC; Kiecker F; Loquai C; Meier F; Tomsitz D; Brenner N; Niesert AC; Thonke R; Hauschild A; Berking C
    Ann Oncol; 2017 Dec; 28(12):3104-3106. PubMed ID: 28950303
    [No Abstract]   [Full Text] [Related]  

  • 36. Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy.
    Gambichler T; Stockfleth E; Susok L
    J Immunother Cancer; 2018 Oct; 6(1):113. PubMed ID: 30376886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
    Donaldson M; Owen JL; Choi JN
    JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
    [No Abstract]   [Full Text] [Related]  

  • 38. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
    Irwin DE; Davis B; Bell JA; Galaznik A; Garcia-Ribas I
    J Comp Eff Res; 2019 Jan; 8(2):81-90. PubMed ID: 30547675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
    Hammami MB; Gill R; Thiruvengadam N; Oh DY; Beck K; Mahadevan U; Kattah MG
    Dig Dis Sci; 2019 Mar; 64(3):685-688. PubMed ID: 30778872
    [No Abstract]   [Full Text] [Related]  

  • 40. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
    Lasocki A; Smith K
    J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.